George Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific region

George Clinical cares for its employees, enables business continuity, and builds on its expertise, giving it a competitive industry advantage.

SAN ANTONIO, May 4, 2023 /PRNewswire/ — Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in Kidney research, Oncology and Neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has its roots. It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects. A sustainable skilled workforce inherently ensures quality outcomes for clients and patients. High employee retention rates also result in new hires through current employee referrals and, more importantly, lower project downtime risks, reducing potential costs from replacing and training new hires.  Unlike larger contract research organizations (CROs), the company promotes a healthy work-life balance for its employees where they do not operate like machines when executing a trial.

George Clinical upholds its agility and responsiveness towards clients with nearly 500 employees, making it more flexible, adaptable, and faster than competitors with more employees. The company stands out in the industry as it works hard to deliver high-quality scientific services while identifying solutions for big biopharma. It meets with clients to assess their needs and develop tailored solutions with roadmaps for seamless execution, establishing ongoing trust with customers for long-lasting relationships. It links the science of an academic research organization (ARO) with a CRO’s global operational processes to meet standard operating procedures.

Azza Fazar, Frost & Sullivan best practices research analyst, observed, “George Clinical combines its connections with AROs and scientific expertise to find suitable sites and investigator networks, a unique competitive differentiator. The company facilitates faster patient-centric recruitment for its clients by bringing the best of both worlds.”

George Clinical works closely with customers during the pre- and post-purchase journey, offering support and guidance to achieve clinical trial excellence within specific therapeutic areas. It excels in creating brand awareness fueled by its exceptional operational strategies and customer-centric design, thus, achieving more leads. Its sterling reputation and customer-centric framework have led to its coveted preferred partner status. Additionally, it established a central monitoring team in India for cost-effectiveness, enabling it to monitor and prove the effectiveness of clinical trial trends across countries. With its long-standing GKPTN network access to a range of chronic kidney disease patients, client-focused oncology trial strategies and geographies, and best practice implementation, it outpaces competitors to lead the APAC CRO sector.

“George Clinical provides a human touch to its projects, ensuring quality outcomes for clients and patients. It develops and implements its growth strategies with customers in mind, solidifying its reputation in the sector,” noted Umesh Lal, Frost & Sullivan industry analyst. With its strong overall performance, George Clinical earns Frost & Sullivan’s 2023 APAC Competitive Leadership Award in the contract research organization industry.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and enables the development of new products and applications. The award recognizes the high sector acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in various regional and global sectors for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry experts compare sector participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Tarini Singh
P: +91-9953764546
E: [email protected]

About George Clinical
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 450 people managing 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials.    

For more information, contact:
Matthew Reabold
Head, US Business Development
T +1-760-645-0496
E [email protected] 
W |


SOURCE Frost & Sullivan

第三季酒店業僱員數量升兩成 人資需求增加





新華社北京11月29日電 美國上周迎來“黑色星期五”購物周。據路透社28日報道,今年“黑五”購物周堪稱數年來“最便宜”,大批消費者受零售商的大力促銷吸引,多番比價、“精明”購物。





【息息相關】REITs 時代



新華社北京11月26日電 普華永道會計師事務所中國資深經濟學家趙廣彬日前表示,隨著政府採取的一系列政策措施發力顯效以及私營部門投資增長,2024年中國經濟增速有望超過今年。






新華社加沙/耶路撒冷11月24日電 當地時間24日上午7時(北京時間13時),巴勒斯坦伊斯蘭抵抗運動(哈馬斯)和以色列在加沙地帶的臨時停火協議生效。雙方將休戰4天。





澳門大學社會科學學院政府與公共行政學系副教授Francisco Leandro是“一帶一路”研究領域的權威專家。在接受採訪時,他預計該倡議將進一步改進,包括更看重“綠色絲綢之路”維度。








澳門貿易投資促進局組織一行近50人的澳門企業家代表團4日赴滬參加第六屆中國國際進口博覽會,這是澳門連續第6年組織 本地企業參與進博會。 澳門特區行政長官賀一誠受邀於4日至5日赴上海,出席第六屆進博會開幕式及相關活動。